Synthesis of [Based on systematic review] evidence on health effects Measuring and [Health effects should be expressed valuing health in QALYs. The EQ-5D is the effects preferred measure of health-related quality of life in adults.] Source of data for [Reported directly by patients and/or carers] measurement of health-related quality of life Source of [Representative sample of the UK preference data population] for valuation of changes in health-related quality of life [An additional QALY has the same Equity considerations weight regardless of the other characteristics of the individuals receiving the health benefit] Evidence on [Costs should relate to NHS and PSS resource use and resources and should be valued costs using the prices relevant to the NHS and PSS] Discounting [The same annual rate for both costs and health effects (currently 3.5%)]
Synthesis of evidence on health effects [Based on systematic review] Measuring and valuing health effects [Health effects should be expressed in QALYs. The EQ-5D is the preferred measure of health-related quality of life in adults.] Source of data for measurement of health-related quality of life [Reported directly by patients and/or carers] Source of preference data for valuation of changes in health-related quality of life [Representative sample of the UK population] Equity considerations [An additional QALY has the same weight regardless of the other characteristics of the individuals receiving the health benefit] Evidence on resource use and costs [Costs should relate to NHS and PSS resources and should be valued using the prices relevant to the NHS and PSS] Discounting [The same annual rate for both costs and health effects (currently 3.5%)]
company-evidence-submission-summary-template-for-committee-apr-17.docx